BETHESDA, Md., July 24, 2014 /PRNewswire/ -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that the Company will issue a business update for the period ending June 30, 2014 on Monday, August 18, 2014 for shareholders. Management has scheduled a conference call at 10 a.m. ET on Monday, August 18, 2014 to discuss the company's progress to date, to be led by the company's CEO, Anthony Hayes.

Spherix Logo

Following prepared remarks, management will address questions that have been submitted via email prior to the call. Interested parties may email questions to spex@haydenir.com. Management will answer as many appropriate and relevant questions as time allows.

Conference call details are as follows:

  • Time: 10 a.m. ET
  • Date: Monday, August 18, 2014
  • Dial-in: 1-877-879-6209 (domestic) or 1-719-325-4839 (international)
  • Replay: from 1 p.m. ET on August 18, 2014 until August 25, 2014. For the replay, please dial 1-877-870-5176 (domestic), or 1-858-384-5517 (international), and use the replay access code, 8033187.
  • Webcast: www.spherix.com or http://public.viavid.com/index.php?id=110103.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Investor Relations Contact:
Hayden IR
Brett Mass
Phone: (646) 536-7331
Email: brett@haydenir.com 
www.haydenir.com

Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com 
www.spherix.com

Logo - http://photos.prnewswire.com/prnh/20131104/PH08853LOGO

SOURCE Spherix Incorporated

Copyright 2014 PR Newswire

Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alkido Pharma Charts.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alkido Pharma Charts.